ArticleCurrent opinion in biomedical engineering2021
Theranostic biomaterials for tissue engineering.
Article in Current opinion in biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- LLMs uncover 6M1@C60's therapeutic targets: inhibiting atherosclerotic progression via NRF2/HO-1/GPX4 axis-mediated ferroptosis suppression.Journal of nanobiotechnology · 2026Article
- From bone replacement to regeneration. A biomaterials started journey.Materials today. Bio · 2026Review
- Implantation of engineered adipocytes suppresses tumor progression in cancer models.Nature biotechnology · 2025Article
- Review
- Encapsulation of β-NGF in injectable microrods for localized delivery accelerates endochondral fracture repair.Frontiers in bioengineering and biotechnology · 2023Article
- Engineered Protein-Iron Oxide Hybrid Biomaterial for MRI-traceable Drug Encapsulation.Molecular systems design & engineering · 2022Article
- Biomaterials to enhance stem cell transplantation.Cell stem cell · 2022Review
- AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Bone tissue engineering supported by bioprinted cell constructs with endothelial cell spheroids.Theranostics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tissue engineering strategies, notably biomaterials, can be modularly designed and tuned to match specific patient needs. Although many challenges within tissue engineering remain, the incorporation of diagnostic strategies to create theranostic (combined therapy and diagnostic) biomaterials presents a unique platform to provide dual monitoring and treatment capabilities and advance the field toward personalized technologies. In this review, we summarize recent developments in this young field of regenerative theranostics and discuss the clinical potential and outlook of these systems from a tissue engineering perspective. As the need for precision and personalized medicines continues to increase to address diseases in all tissues in a patient-specific manner, we envision that such theranostic platforms can serve these needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.